Medical News

RSS

HIRC recognizes CDPHP for offering best disease management program in upstate New York

Health Dialog Services Corporation, a leading provider of healthcare decision programs, today announced that its client, Capital District Physicians’ Health Plan, Inc. (CDPHP®), has been recognized by the Health Industries Research Cos. (HIRC) for offering the best disease management program in upstate New York.

16 Nov 2009

First-quarter fiscal 2010 results announced by IsoRay

IsoRay Inc. a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the first quarter of fiscal year 2010, ended September 30, 2009.

16 Nov 2009

Bright Now! Dental announces the opening of Castle Dental office in Kyle

Bright Now! Dental Inc., the nation’s leading provider of business support services to dentists, announces the grand opening of a new Castle Dental office in Kyle. Located at 5103 Kyle Center Drive in the Kyle Corners Shopping Center, the office provides families with a convenient, comfortable environment where they can receive the latest in comprehensive, full-serve quality dental care.

16 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Windhover Information selects Oncothyreon's PX-866 among top 10 oncology projects for partnering

Oncothyreon Inc. today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Advanced Cell Technology to raise funds through private placements

Advanced Cell Technology, Inc., announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million.

16 Nov 2009

Positive results from Winston Laboratories' Civamide Patch trial

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN).

16 Nov 2009

Neighborhood Healthcare selects eClinicalWorks EMR and PM solution

eClinicalWorks®, a market leader in ambulatory clinical systems, today announced that Neighborhood Healthcare, which serves Riverside and San Diego counties, has selected eClinicalWorks unified electronic medical records (EMR) and practice management (PM) solution along with eClinicalWorks Enterprise Business Optimizer’s (eBO) enhanced reporting capabilities for its 115 providers across 11 locations.

16 Nov 2009

CCSA to focus on role of treatment systems at Canada's Issues of Substance 2009 conference

The Canadian Centre on Substance Abuse (CCSA) today announced that it will open Issues of Substance (IOS) 2009, Canada's biennial conference on substance abuse, with a focus on the role of treatment systems. More than 13 sessions will examine the role of treatment from a variety of perspectives, including the Models of Care project in the UK, the National Treatment Strategy in Canada (NTS) and case study and research presentations reviewing the effectiveness of a variety of integrated programs in Canada.

16 Nov 2009

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Three platelet function tests all identified heart patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pre-treated with two anti-clotting medications before coronary stenting, researchers reported at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Alcohol mixed with energy drinks: Higher prevalence of sexual assault and injury in college students

Emergency physician Mary Claire O'Brien, M.D., of Wake Forest University Baptist Medical Center, has done extensive research on the risks and dangers of alcoholic energy drinks (AEDs).

16 Nov 2009

Enrollment complete in Cytori Therapeutics' international breast cancer reconstruction study

Cytori Therapeutics completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer.

16 Nov 2009

Sinobiopharma's 23 generic drugs on China's National Essential Drugs List

Sinobiopharma, Inc. is pleased to announce that 23 generic drugs for which the Company has production rights are listed in China's National Essential Drugs List, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China.

16 Nov 2009

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Fewer than one-third of patients with heart failure are taking the three types of medications that are most effective in prolonging life and improving quality of life. The November issue of Mayo Clinic Health Letter provides an overview of treatments recommended by national guidelines.

16 Nov 2009

Sunlight Saunas renamed as Sunlighten

After a thorough, long-term strategic brand-building process, Sunlighten(TM) has been chosen as the new name for health & wellness leader Sunlight Saunas(TM). Under the same ownership and with a renewed sense of corporate mission, Sunlighten has plans for a host of cutting-edge wellness products over the coming years, including advances in its line of long-celebrated infrared saunas.

16 Nov 2009

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm Corporation today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

16 Nov 2009

WhereToFindCare web site offers tips for evaluating health care facilities and providers

Consumers now have a free, convenient way to gain control over their health care options. Through the use of the national Web site, WhereToFindCare.com, consumers who share their health care experiences will contribute to quality ratings of hospitals, doctors, nursing homes, diagnostic centers and other health care providers.

16 Nov 2009

PanGenex finalizes partnership with BulovaTech Labs

PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., (“LABS”), a wholly-owned subsidiary of Bulova Technologies Group Inc.

16 Nov 2009

Medical News

HIRC recognizes CDPHP for offering best disease management program in upstate New York

First-quarter fiscal 2010 results announced by IsoRay

Bright Now! Dental announces the opening of Castle Dental office in Kyle

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

Windhover Information selects Oncothyreon's PX-866 among top 10 oncology projects for partnering

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Advanced Cell Technology to raise funds through private placements

Positive results from Winston Laboratories' Civamide Patch trial

Neighborhood Healthcare selects eClinicalWorks EMR and PM solution

CCSA to focus on role of treatment systems at Canada's Issues of Substance 2009 conference

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Myeloma UK launches innovative clinical trial network

Alcohol mixed with energy drinks: Higher prevalence of sexual assault and injury in college students

Enrollment complete in Cytori Therapeutics' international breast cancer reconstruction study

Sinobiopharma's 23 generic drugs on China's National Essential Drugs List

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Sunlight Saunas renamed as Sunlighten

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

WhereToFindCare web site offers tips for evaluating health care facilities and providers

PanGenex finalizes partnership with BulovaTech Labs

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News